NEWS & MEDIA

StemTek Therapeutics, a leading Spanish biotech start up with a stem cell centric approach, today announced an important collaboration with the Institute for Advanced Chemistry of Catalonia (IQAC) part of the Spanish National Research Council (CSIC). The agreement enables greater access and deeper collaboration between the private and the public sector to screen libraries of compounds from the Institute for Advanced Chemistry of Catalonia in order to identify those that can be used ...
In this interview, Eva Caballero talks about the recent news from Silicon Valley about the estratosfera valuation of Stemcntrx, start up dedicated to drug development in cancer targeting cancer stem cells. Angel Garcia Martin talks about how cancer stem cells are indeed a new frontier for anti-cancer drug development and how noe there is a revamped interest in pharma industry for novel therapeutics that control the growth of these populations. This is precisely the mission of StemTek The...

Silicon Valley Invests Big in Cancer Stem Cells

Bilbao, Spain - September 08, 2015

Three billion dollars, largest valuation for a biotech start-up that targets cancer stem cells. We just read in MIT Technology Review that Silicon Valley heavyweights Peter Thiel and Elon Musk, investor and CEO of Tesla, just invested in an unheard of biotech start up which represents the biggest biotech valuation to date aimed at cancer stem cell treatments. Peter Thiel, one of the first outside investors in Facebook, just invested $200 million into Stemcentrx, his fund’s la...
I have been engaged recently in discussions with several high profile researchers and scientists from pharma industry on how to test for drugs that target cancer stem cells. Targeted based screening, the preferred strategy for pharma, relies on targets that are validated on cancer stem cells, which there are only a handful (maybe SHH pathway, Wnt pathway or TGFb come to mind). After the initial flurry of activity in the field a decade ago, the biology of cancer stem cells has proven comple...

Cancer stem cells, mitochondria & antibiotics

Bilbao, Spain - April 22, 2015

Why not treat cancer like an infectious disease?   This question, that could sound “naive”, was actually asked by a schoolgirl to her father.  It might not have had any impact on other family but in this case, the father was Michael P. Lisanti, a reputed cancer scientist, now director of The Breatkthrough Breast Cancer Research Unit at the University of Manchester.  His group described in a previous work the high dependence of cancer stem cell...
Back to top